Dyadic in tech transfer pact with S. Africa vaccine developer

 Potential for Affordable COVID-19 Immunization Coverage in Underserved African Countries

• Arrangement includes C1 COVID-19 vaccine technology transfer and licensing agreement

• Provides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III clinical trials

• Establishes co-development basis for researching, developing and manufacturing multiple other C1 produced vaccines in addition to DYAI-100

• Intends to reduce African dependence on foreign vaccine suppliers

• Combined with previous C1 COVID-19 vaccine collaborations in India and South Korea (including Southeast Asia), this agreement further supports the potential for C1 produced COVID-19 immunization coverage to more than 40% of the world’s population

https://finance.yahoo.com/news/dyadic-announces-technology-transfer-licensing-122000185.html